Stage Iii Non-Small Cell Lung Cancer: Who Passes The Threshold?

e17502 Background: Objective: The objective of the study is to indentify the patients diagnosed of stage III non-small cell lung cancer (NSCLC) in Puerta de Hierro Madrid Hospital (Spain) between 2000 and 2008, who had longer overall survival rates (more than 24 months) and longer time to progression after completing initial treatment. Methods: We revised all cases of NSLC seen in our hospital, and of those, selected 147, the ones diagnosed, treated and followed completely in our hospital. We reviewed the age at diagnosis, initial staging, modalities of treatment received in each case, time to progression, site of development of metastasis, time to relapse and overall survival. The time of monitoring was from date of diagnosis until death date or, until transferral to palliative care clinics. Results: We revised 966 histories of patients, of which 147 were diagnosed stage III, treated and followed in our hospital. Most common hystological type were Epidermoid Carcinomas (54.3% versus 21.7% of adenocarcinomas), and were diagnosed at older ages. 45.6% underwent surgery, most of them (41.2%) were treated before with neoadyuvant chemo or radiotherapy, with a median survival of 32.4 months, with an overall survival interval very wide, from 20 days until more than 8 years. Among these patients were the ones who survived more than 24 moths after diagnosis, and those had Ps 0 -1 at diagnosis, less comorbidities and had the same proportion of stage IIIA and IIIB stages. 53% of patients were only treated with cisplatin-based chemotherapy or radiotherapy at 60Gy, and in these cases, the median overall survival was shorter: 9.5 months Conclusions: In our study, neoadyuvant therapies and the protocols used are the most accepted in international guidelines. The patients who underwent chemotherapy and surgery lived much more and they had better Performance Status at diagnosis, so we can conclude that chemotherapy and surgery, if possible, are a good treatment option with longer global survival. Definitive chemotherapy and radiotherapy should be better reserved for those patients who are not candidates for surgery.